Form 4: MAIA Director Acquires 25,206 Stock Options

Sentiment:

Insider Transaction Report 5 January 2026 8:41 AM

📋All filings for Maia Biotechnology, INC

MAIA Biotechnology, Inc. Director Cristian Luput was granted 25,206 stock options exercisable at $1.53 per share, vesting immediately.

Summary

Cristian Luput, a Director of MAIA Biotechnology, Inc., acquired 25,206 derivative securities in the form of stock options.
The options were granted on December 31, 2025, pursuant to the company's 2021 Equity Incentive Plan.
Each option allows the purchase of one share of common stock at an exercise price of $1.53.
The options vested 100% on the grant date (December 31, 2025) and are exercisable beginning as of that date.
The options have an expiration date of December 31, 2035.
Following this transaction, Mr. Luput beneficially owns 25,206 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating management's continued commitment and alignment with shareholder interests, especially with immediate vesting. It's a routine compensation event.

Positives

Director Cristian Luput received a grant of 25,206 stock options, indicating continued alignment of management interests with shareholder value.
The options vested 100% on the grant date, providing immediate exercisability.

Future Outlook

Industry Context

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Equity Incentive Plan Utilization	The options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, demonstrating the ongoing use of the plan for director compensation.	12/31/2025	Reinforces the company's established compensation framework for aligning director incentives with long-term shareholder value.

Stakeholder Impact

Shareholders: The grant of options to a director aligns their interests with shareholders, as the options gain value if the stock price increases. It also represents potential future dilution if exercised.
Employees: The 2021 Equity Incentive Plan is used for compensation, which can motivate key personnel.

Key Dates

Date	Description
12/31/2025	Date of option grant and transaction date.
12/31/2025	Date options became exercisable and 100% vested.
01/05/2026	Date the Form 4 was signed and filed.
12/31/2035	Expiration date of the stock options.

Recommendation

hold

This Form 4 reports a routine grant of stock options to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a standard governance event.

Keywords

MAIA Biotechnology, MAIA, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Incentive Plan, Cristian Luput

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.